Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors https://t.co/2f77j3RIAk
RT @CellworksLife: Preclinical Characterization of HPN536 for the Treatment of Mesothelin-Expressing Solid #Tumors. https://t.co/xEjTEmcA4r
Preclinical Characterization of HPN536 for the Treatment of Mesothelin-Expressing Solid #Tumors. https://t.co/xEjTEmcA4r
Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors https://t.co/bUbdpC37pA
Preclinical Characterization of HPN536, a Trispecific, T Cell-activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors https://t.co/HDStUCczk4
Preclinical Characterization of HPN536, a Trispecific, T Cell-activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors https://t.co/UxUrv6hq5j